Supernus Pharmaceuticals (NASDAQ:SUPN)‘s stock had its “buy” rating reiterated by investment analysts at B. Riley in a research note issued on Thursday, January 18th, MarketBeat.com reports. They currently have a $54.00 price target on the specialty pharmaceutical company’s stock. B. Riley’s price objective points to a potential upside of 39.72% from the stock’s previous close.
Several other equities research analysts also recently weighed in on the company. Zacks Investment Research downgraded Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, January 12th. BidaskClub upgraded Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 11th. Janney Montgomery Scott upgraded Supernus Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $47.00 price target for the company in a research note on Monday, December 4th. ValuEngine cut Supernus Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Friday, December 1st. Finally, Stifel Nicolaus upgraded Supernus Pharmaceuticals from a “hold” rating to a “buy” rating and set a $47.00 price objective for the company in a research report on Tuesday, November 7th. Four investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $51.36.
Supernus Pharmaceuticals (NASDAQ:SUPN) opened at $38.65 on Thursday. The stock has a market capitalization of $1,920.00, a P/E ratio of 35.14 and a beta of 1.08. Supernus Pharmaceuticals has a fifty-two week low of $24.65 and a fifty-two week high of $50.04.
Supernus Pharmaceuticals (NASDAQ:SUPN) last posted its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported $0.29 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.27 by $0.02. The business had revenue of $80.40 million during the quarter, compared to the consensus estimate of $78.74 million. Supernus Pharmaceuticals had a return on equity of 26.37% and a net margin of 20.98%. The firm’s revenue was up 41.5% compared to the same quarter last year. research analysts predict that Supernus Pharmaceuticals will post 1.07 EPS for the current fiscal year.
In related news, VP Victor Vaughn sold 55,000 shares of the stock in a transaction on Tuesday, January 2nd. The stock was sold at an average price of $40.11, for a total transaction of $2,206,050.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Padmanabh P. Bhatt sold 20,000 shares of the firm’s stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $48.04, for a total value of $960,800.00. Following the completion of the sale, the vice president now directly owns 32,500 shares in the company, valued at $1,561,300. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 165,750 shares of company stock worth $7,133,973. Corporate insiders own 6.70% of the company’s stock.
Several institutional investors have recently added to or reduced their stakes in the company. Cortina Asset Management LLC raised its holdings in shares of Supernus Pharmaceuticals by 77.7% in the 4th quarter. Cortina Asset Management LLC now owns 166,321 shares of the specialty pharmaceutical company’s stock worth $6,628,000 after purchasing an additional 72,721 shares during the period. OppenheimerFunds Inc. raised its holdings in shares of Supernus Pharmaceuticals by 3.9% in the 4th quarter. OppenheimerFunds Inc. now owns 412,012 shares of the specialty pharmaceutical company’s stock worth $16,419,000 after purchasing an additional 15,538 shares during the period. BlackRock Inc. raised its holdings in shares of Supernus Pharmaceuticals by 1.8% in the 4th quarter. BlackRock Inc. now owns 6,902,230 shares of the specialty pharmaceutical company’s stock worth $275,054,000 after purchasing an additional 120,394 shares during the period. Schroder Investment Management Group raised its holdings in shares of Supernus Pharmaceuticals by 61.0% during the 4th quarter. Schroder Investment Management Group now owns 13,624 shares of the specialty pharmaceutical company’s stock valued at $543,000 after buying an additional 5,160 shares during the period. Finally, Rhumbline Advisers raised its holdings in shares of Supernus Pharmaceuticals by 17.2% during the 4th quarter. Rhumbline Advisers now owns 113,387 shares of the specialty pharmaceutical company’s stock valued at $4,518,000 after buying an additional 16,630 shares during the period. Institutional investors own 98.20% of the company’s stock.
ILLEGAL ACTIVITY NOTICE: This report was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this report on another website, it was illegally stolen and republished in violation of U.S. and international copyright and trademark laws. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2018/02/13/b-riley-reaffirms-buy-rating-for-supernus-pharmaceuticals-supn.html.
About Supernus Pharmaceuticals
Supernus Pharmaceuticals, Inc is a pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. The Company offers Oxtellar XR (extended-release oxcarbazepine) and Trokendi XR (extended-release topiramate), its two treatments for patients with epilepsy.
Receive News & Ratings for Supernus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Supernus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.